Evolving Treatment Paradigms in HR+/HER2- MBC

**Conclusion**: The treatment paradigm for HR+/HER2- MBC is evolving from a uniform CDK4/6i + ET backbone toward a biomarker-informed, multi-line sequencing strategy incorporating next-generation endocrine agents (e.g., elacestrant), PI3K/AKT pathway inhibitors, and antibody-drug conjugates (ADCs), with the goal of delaying chemotherapy and maintaining quality of life. --- ## Clinical Evidence & Efficacy ### First-Line Standard of Care The combination of a **CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET)** remains the established first-line (1L) standard of care for HR+/HER2- MBC [1][3][5][10]. This regimen approximately doubles progression-free survival (PFS) compared to ET alone, with a PFS of ~14–16 months for letrozole alone versus significantly longer with combination therapy [10]. However, 15–25% of patients exhibit intrinsic resistance and progress rapidly regardless of the CDK4/6i used [10]. ### Post-CDK4/6i Landscape (2L and Beyond) The optimal sequence after progression on 1L CDK4/6i + ET is the central area of evolution. Key components include: - **Biomarker-Guided Targeted Therapy**: The ASCO 2025 Educational Book emphasizes that therapies informed by **PI3K/AKT pathway alterations** and **ESR1 mutations** are now key components of post-CDK4/6i management [3]. - **Next-Generation Endocrine Agents**: **Elacestrant**, an oral selective estrogen receptor degrader (SERD), is an option for patients with *ESR1* mutations, which develop in 20–40% of patients treated with aromatase inhibitors for MBC [7]. - **Antibody-Drug Conjugates (ADCs)**: ADCs are reshaping the treatment continuum. Notably, up to 60% of mBC historically classified as HER2-negative are actually **HER2-low**, expanding eligibility for novel HER2-targeted ADCs like trastuzumab deruxtecan (T-DXd) [2][8]. NICE guidelines recommend T-DXd for treating HER2-low metastatic breast cancer after chemotherapy [8]. - **Chemotherapy**: While still used, real-world data demonstrate that chemotherapy provides relatively limited survival benefit, which decreases with each additional line [9]. The goal of 2L+ therapy is often to **delay time-to-chemotherapy** and maintain quality of life [1]. ### Real-World Practice Patterns A survey of 150 US oncologists (RETRACT) found that most follow recommended best practices, but substantial minorities diverge on: - Definition and treatment of visceral crisis - Ideal treatment for endocrine resistance - Routine use of next-generation sequencing for biomarker testing [4] --- ## Mechanism of Action (Background) HR+/HER2- breast cancer is defined by estrogen receptor (ER) and/or progesterone receptor positivity [7]. The foundational 1L therapy combines: - **Endocrine Therapy (ET)**: Blocks estrogen signaling (e.g., aromatase inhibitors, fulvestrant). - **CDK4/6i**: Inhibits cell cycle progression by targeting cyclin-dependent kinases 4 and 6, which are critical for cell division in ER+ breast cancer [10]. Resistance to ET can be acquired via **ESR1 mutations** (e.g., Y537S, D538G), which lead to constitutive ER activation and are associated with more aggressive disease and poor outcomes [7]. Novel agents like elacestrant (SERD) and H3B-6545 (selective ERα covalent antagonist, SERCA) are designed to overcome this resistance [7]. --- ## Guideline Recommendations - **1L Therapy**: CDK4/6i + ET is the established standard [1][3][5]. - **Post-Progression**: The ASCO 2025 Educational Book advocates for a **personalized, biomarker-informed approach** using molecular markers (PI3K/AKT, *ESR1*) to guide selection of targeted therapies and ADCs [3]. - **HER2-Low**: NICE recommends T-DXd for HER2-low metastatic breast cancer after prior chemotherapy [8]. --- ## Critical Gaps - **Optimal Sequencing**: Despite positive outcomes with 1L CDK4/6i + ET, the optimal sequence of therapies following disease progression remains unclear [2]. - **Real-World Data**: There is a paucity of data on real-world treatment patterns in the 2L setting [1]. - **Cross-Resistance**: The expanding role of ADCs raises questions about cross-resistance and sequencing considerations that are still under investigation [3]. - **Biomarker Testing**: Routine use of next-generation sequencing for biomarker testing is not yet universally adopted in real-world practice [4]. --- ## Conclusion The HR+/HER2- MBC treatment paradigm is shifting from a one-size-fits-all CDK4/6i + ET backbone to a dynamic, biomarker-driven sequencing strategy that integrates next-generation endocrine agents, PI3K/AKT inhibitors, and ADCs to optimize outcomes across multiple lines of therapy. --- *This content is AI-generated based on retrieved literature and is intended for clinical reference only. Clinicians should verify sources and apply individual patient judgment when making treatment decisions.*